{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:30:33Z","timestamp":1769833833110,"version":"3.49.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s00198-010-1223-4","type":"journal-article","created":{"date-parts":[[2010,5,17]],"date-time":"2010-05-17T13:48:51Z","timestamp":1274104131000},"page":"1657-1680","source":"Crossref","is-referenced-by-count":79,"title":["Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club"],"prefix":"10.1007","volume":"21","author":[{"given":"J.-J.","family":"Body","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Boutsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Devogelaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Goemaere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-M.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rozenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,18]]},"reference":[{"key":"1223_CR1","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1001\/archinte.1989.00390110045010","volume":"149","author":"SR Cummings","year":"1989","unstructured":"Cummings SR, Black DM, Rubin SM (1989) Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149:2445\u20132448","journal-title":"Arch Intern Med"},{"key":"1223_CR2","first-page":"373","volume":"11","author":"P Autier","year":"2000","unstructured":"Autier P, Haentjens P, Bentin J, Baillon JM, Grivegnee AR, Closon MC, Boonen S (2000) Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group Osteoporos Int 11:373\u2013380","journal-title":"Belgian Hip Fracture Study Group. Osteoporos Int"},{"key":"1223_CR3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1210\/er.2001-1002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Tugwell P, Wells G, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 23:496\u2013507","journal-title":"Endocr Rev"},{"key":"1223_CR4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399\u2013428","journal-title":"Osteoporos Int"},{"key":"1223_CR5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00198-004-1812-1","volume":"16","author":"S Boonen","year":"2005","unstructured":"Boonen S, Body JJ, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY (2005) Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 16:239\u2013254","journal-title":"Osteoporos Int"},{"key":"1223_CR6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399\u2013428","journal-title":"Osteoporos Int"},{"key":"1223_CR7","first-page":"612","volume":"64","author":"A Neuprez","year":"2009","unstructured":"Neuprez A, Johansson H, Kanis JA, McCloskey EV, Oden A, Bruyere O, Hiligsmann M, Devogelaer JP, Kaufman JM, Reginster JY (2009) Rationalisation du remboursement des m\u00e9dicaments de l'ost\u00e9oporose: de la mesure isol\u00e9e de la densit\u00e9 osseuse \u00e0 l'int\u00e9gration des facteurs cliniques de risque fracturaire. Validation de l'algorithme FRAX\u00ae. Rev Med Liege 64:612\u2013619","journal-title":"Rev Med Liege"},{"key":"1223_CR8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bone.2007.10.005","volume":"42","author":"R Rizzoli","year":"2008","unstructured":"Rizzoli R, Boonen S, Brandi ML, Burlet N, Delmas P, Reginster JY (2008) The role of calcium and vitamin D in the management of osteoporosis. Bone 42:246\u2013249","journal-title":"Bone"},{"key":"1223_CR9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00223-005-0009-8","volume":"78","author":"S Boonen","year":"2006","unstructured":"Boonen S, Bischoff-Ferrari HA, Cooper C, Lips P, Ljunggren O, Meunier PJ, Reginster JY (2006) Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif Tissue Int 78:257\u2013270","journal-title":"Calcif Tissue Int"},{"key":"1223_CR10","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1001\/jama.1994.03520240070044","volume":"272","author":"NIH Consensus conference","year":"1994","unstructured":"NIH Consensus conference (1994) Optimal calcium intake. NIH consensus development panel on optimal calcium intake. JAMA 272:1942\u20131948","journal-title":"JAMA"},{"key":"1223_CR11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00223-008-9148-z","volume":"83","author":"SD Thomas","year":"2008","unstructured":"Thomas SD, Need AG, Tucker G, Slobodian P, O'Loughlin PD, Nordin BE (2008) Suppression of parathyroid hormone and bone resorption by calcium carbonate and calcium citrate in postmenopausal women. Calcif Tissue Int 83:81\u201384","journal-title":"Calcif Tissue Int"},{"key":"1223_CR12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jbspin.2003.09.004","volume":"70","author":"X Deprez","year":"2003","unstructured":"Deprez X, Fardellone P (2003) Nonpharmacological prevention of osteoporotic fractures. Joint Bone Spine 70:448\u2013457","journal-title":"Joint Bone Spine"},{"key":"1223_CR13","doi-asserted-by":"crossref","unstructured":"Lips P, Bouillon R, van Schoor N, Vanderschueren D, Verschueren S, Kuchuk N, Milisen K, Boonen S (2009) Reducing fracture risk with calcium and vitamin D. Clin Endocrinol. doi: 10.1111\/j.0300-0664.2009.03701.x","DOI":"10.1111\/j.0300-0664.2009.03701.x"},{"key":"1223_CR14","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJM199212033272305","volume":"327","author":"MC Chapuy","year":"1992","unstructured":"Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ (1992) Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327:1637\u20131642","journal-title":"N Engl J Med"},{"key":"1223_CR15","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/bmj.308.6936.1081","volume":"308","author":"MC Chapuy","year":"1994","unstructured":"Chapuy MC, Arlot ME, Delmas PD, Meunier PJ (1994) Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 308:1081\u20131082","journal-title":"BMJ"},{"key":"1223_CR16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s001980200023","volume":"13","author":"MC Chapuy","year":"2002","unstructured":"Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, Garnero P, Meunier PJ (2002) Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 13:257\u2013264","journal-title":"Osteoporos Int"},{"key":"1223_CR17","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1056\/NEJM199709043371003","volume":"337","author":"B Dawson-Hughes","year":"1997","unstructured":"Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65\u00a0years of age or older. N Engl J Med 337:670\u2013676","journal-title":"N Engl J Med"},{"key":"1223_CR18","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/0003-4819-124-4-199602150-00003","volume":"124","author":"P Lips","year":"1996","unstructured":"Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM (1996) Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 124:400\u2013406","journal-title":"Ann Intern Med"},{"key":"1223_CR19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.326.7387.469","volume":"326","author":"DP Trivedi","year":"2003","unstructured":"Trivedi DP, Doll R, Khaw KT (2003) Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326:469","journal-title":"BMJ"},{"key":"1223_CR20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00298497","volume":"51","author":"RJ Heikinheimo","year":"1992","unstructured":"Heikinheimo RJ, Inkovaara JA, Harju EJ, Haavisto MV, Kaarela RH, Kataja JM, Kokko AM, Kolho LA, Rajala SA (1992) Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 51:105\u2013110","journal-title":"Calcif Tissue Int"},{"key":"1223_CR21","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1001\/jama.293.18.2257","volume":"293","author":"HA Bischoff-Ferrari","year":"2005","unstructured":"Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B (2005) Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293:2257\u20132264","journal-title":"JAMA"},{"key":"1223_CR22","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1210\/jc.2006-1404","volume":"92","author":"S Boonen","year":"2007","unstructured":"Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92:1415\u20131423","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/archinternmed.2008.600","volume":"169","author":"HA Bischoff-Ferrari","year":"2009","unstructured":"Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, Thoma A, Kiel DP, Henschkowski J (2009) Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 169:551\u2013561","journal-title":"Arch Intern Med"},{"key":"1223_CR24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(07)61342-7","volume":"370","author":"BM Tang","year":"2007","unstructured":"Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50\u00a0years and older: a meta-analysis. Lancet 370:657\u2013666","journal-title":"Lancet"},{"key":"1223_CR25","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1359\/jbmr.060715","volume":"21","author":"S Adami","year":"2006","unstructured":"Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R (2006) Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 21:1565\u20131570","journal-title":"J Bone Miner Res"},{"key":"1223_CR26","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00198-006-0073-6","volume":"17","author":"M Rossini","year":"2006","unstructured":"Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914\u2013921","journal-title":"Osteoporos Int"},{"key":"1223_CR27","first-page":"262","volume":"39","author":"S Rozenberg","year":"1994","unstructured":"Rozenberg S, Vandromme J, Kroll M, Pastijn A, Degueldre M (1994) Osteoporosis prevention with sex hormone replacement therapy. Int J Fertil Menopausal Stud 39:262\u2013271","journal-title":"Int J Fertil Menopausal Stud"},{"key":"1223_CR28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321\u2013333","journal-title":"JAMA"},{"key":"1223_CR29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(03)14066-4","volume":"362","author":"PY Scarabin","year":"2003","unstructured":"Scarabin PY, Oger E, Plu-Bureau G (2003) Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362:428\u2013432","journal-title":"Lancet"},{"key":"1223_CR30","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1210\/jc.2008-0450","volume":"93","author":"M Canonico","year":"2008","unstructured":"Canonico M, Bouaziz E, Carcaillon L, Verstuyft C, Guiochon-Mantel A, Becquemont L, Scarabin PY, Estrogen and Thromboembolism Risk (ESTHER) Study Group (2008) Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women. J Clin Endocrinol Metab 93:3082\u20133087","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR31","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0800743","volume":"359","author":"SR Cummings","year":"2008","unstructured":"Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R (2008) The effects of tibolone in older postmenopausal women. N Engl J Med 359:697\u2013708","journal-title":"N Engl J Med"},{"key":"1223_CR32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.maturitas.2008.10.009","volume":"61","author":"A Gompel","year":"2008","unstructured":"Gompel A, Rozenberg S, Barlow DH (2008) The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas 61:227\u2013232","journal-title":"Maturitas"},{"key":"1223_CR33","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1089\/jwh.2008.1246","volume":"10","author":"I Lekander","year":"2009","unstructured":"Lekander I, Borgstr\u00f6m F, Str\u00f6m O, Zethraeus N, Kanis JA (2009) Cost-effectiveness of hormone therapy in the United States. J Womens Health (Larchmt) 10:1669\u20131677","journal-title":"J Womens Health (Larchmt)"},{"key":"1223_CR34","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.bone.2003.12.021","volume":"34","author":"YZ Bagger","year":"2004","unstructured":"Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C (2004) Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34:728\u2013735","journal-title":"Bone"},{"key":"1223_CR35","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1001\/jama.285.11.1482","volume":"285","author":"P Alexandersen","year":"2001","unstructured":"Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C, Fechtenbaum J, Gennari C, Reginster JY (2001) Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 285:1482\u20131488","journal-title":"JAMA"},{"key":"1223_CR36","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/ajcn\/72.3.844","volume":"72","author":"DL Alekel","year":"2000","unstructured":"Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T (2000) Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 72:844\u2013852","journal-title":"Am J Clin Nutr"},{"key":"1223_CR37","first-page":"221","volume":"46","author":"CS Hsu","year":"2001","unstructured":"Hsu CS, Shen WW, Hsueh YM, Yeh SL (2001) Soy isoflavone supplementation in postmenopausal women. Effects on plasma lipids, antioxidant enzyme activities and bone density. J Reprod Med 46:221\u2013226","journal-title":"J Reprod Med"},{"key":"1223_CR38","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1210\/jc.2003-030290","volume":"88","author":"YM Chen","year":"2003","unstructured":"Chen YM, Ho SC, Lam SS, Ho SS, Woo JL (2003) Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. J Clin Endocrinol Metab 88:4740\u20134747","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.292.1.65","volume":"292","author":"S Kreijkamp-Kaspers","year":"2004","unstructured":"Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman A, Lampe JW, van der Schouw YT (2004) Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 292:65\u201374","journal-title":"JAMA"},{"key":"1223_CR40","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1210\/jc.2003-031166","volume":"89","author":"E Nikander","year":"2004","unstructured":"Nikander E, Metsa-Heikkila M, Ylikorkala O, Tiitinen A (2004) Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer. J Clin Endocrinol Metab 89:1207\u20131212","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00198-005-2030-1","volume":"17","author":"E Seeman","year":"2006","unstructured":"Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2006) Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 17:313\u2013316","journal-title":"Osteoporos Int"},{"key":"1223_CR42","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2006.11.001","volume":"40","author":"RR Recker","year":"2007","unstructured":"Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L Jr, Stock JL (2007) Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone 40:843\u2013851","journal-title":"Bone"},{"key":"1223_CR43","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","volume":"96","author":"S Martino","year":"2004","unstructured":"Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751\u20131761","journal-title":"J Natl Cancer Inst"},{"key":"1223_CR44","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","volume":"20","author":"ES Siris","year":"2005","unstructured":"Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR (2005) Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20:1514\u20131524","journal-title":"J Bone Miner Res"},{"key":"1223_CR45","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S8756-3282(01)00706-2","volume":"30","author":"SJ Neele","year":"2002","unstructured":"Neele SJ, Evertz R, De Valk-De RG, Roos JC, Netelenbos JC (2002) Effect of 1\u00a0year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5\u00a0years of treatment in healthy postmenopausal women. Bone 30:599\u2013603","journal-title":"Bone"},{"key":"1223_CR46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125\u2013137","journal-title":"N Engl J Med"},{"key":"1223_CR47","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727\u20132741","journal-title":"JAMA"},{"key":"1223_CR48","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med 333:1437\u20131443","journal-title":"N Engl J Med"},{"key":"1223_CR49","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"1223_CR50","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"1223_CR51","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jama.1997.03540380073035","volume":"277","author":"DB Karpf","year":"1997","unstructured":"Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, Adami S, Harris ST, Santora AC 2nd, Hirsch LJ, Oppenheimer L, Thompson D (1997) Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate osteoporosis treatment study groups. JAMA 277:1159\u20131164","journal-title":"JAMA"},{"key":"1223_CR52","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508\u2013516","journal-title":"Endocr Rev"},{"key":"1223_CR53","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189\u20131199","journal-title":"N Engl J Med"},{"key":"1223_CR54","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5\u00a0years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"key":"1223_CR55","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","volume":"335","author":"PC Groen de","year":"1996","unstructured":"de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016\u20131021","journal-title":"N Engl J Med"},{"key":"1223_CR56","first-page":"1","volume":"12","author":"T Schnitzer","year":"2000","unstructured":"Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC 2nd, Kaur A, Thompson DE, Yates J, Orloff JJ (2000) Therapeutic equivalence of alendronate 70\u00a0mg once-weekly and alendronate 10\u00a0mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1\u201312","journal-title":"Aging (Milano)"},{"key":"1223_CR57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1185\/03007990802648903","volume":"25","author":"RJ Dansereau","year":"2009","unstructured":"Dansereau RJ, Crail DJ, Perkins AC (2009) In vitro disintegration studies of weekly generic alendronate sodium tablets (70\u00a0mg) available in the US. Curr Med Res Opin 25:449\u2013452","journal-title":"Curr Med Res Opin"},{"key":"1223_CR58","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.clinthera.2008.04.018","volume":"30","author":"AC Perkins","year":"2008","unstructured":"Perkins AC, Blackshaw PE, Hay PD, Lawes SC, Atherton CT, Dansereau RJ, Wagner LK, Schnell DJ, Spiller RC (2008) Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects. Clin Ther 30:834\u2013844","journal-title":"Clin Ther"},{"key":"1223_CR59","doi-asserted-by":"crossref","unstructured":"Ringe JD, Moller G (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int. doi: 10.1007\/s00296-009-0940-5","DOI":"10.1007\/s00296-009-0940-5"},{"key":"1223_CR60","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"1223_CR61","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"1223_CR62","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/jc.2002-020400","volume":"88","author":"NB Watts","year":"2003","unstructured":"Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD, Barton I, Calligeros D, Felsenberg D (2003) Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88:542\u2013549","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-003-0042-4","volume":"74","author":"JT Harrington","year":"2004","unstructured":"Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129\u2013135","journal-title":"Calcif Tissue Int"},{"key":"1223_CR64","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","volume":"32","author":"OH Sorensen","year":"2003","unstructured":"Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, Pack S, Wenderoth D, Cooper C, Reginster JY (2003) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32:120\u2013126","journal-title":"Bone"},{"key":"1223_CR65","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1532-5415.2004.52506.x","volume":"52","author":"S Boonen","year":"2004","unstructured":"Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton IP, Delmas P (2004) Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 52:1832\u20131839","journal-title":"J Am Geriatr Soc"},{"key":"1223_CR66","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"1223_CR67","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/er.2001-3002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517\u2013523","journal-title":"Endocr Rev"},{"key":"1223_CR68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","volume":"71","author":"JP Brown","year":"2002","unstructured":"Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103\u2013111","journal-title":"Calcif Tissue Int"},{"key":"1223_CR69","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"IC Chesnut","year":"2004","unstructured":"Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"1223_CR70","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","volume":"65","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2\u00a0year results from the MOBILE study. Ann Rheum Dis 65:654\u2013661","journal-title":"Ann Rheum Dis"},{"key":"1223_CR71","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10067-007-0824-6","volume":"27","author":"JA Stakkestad","year":"2008","unstructured":"Stakkestad JA, Lakatos P, Lorenc R, Sedarati F, Neate C, Reginster JY (2008) Monthly oral ibandronate is effective and well tolerated after 3\u00a0years: the MOBILE long-term extension. Clin Rheumatol 27:955\u2013960","journal-title":"Clin Rheumatol"},{"key":"1223_CR72","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","volume":"54","author":"PD Delmas","year":"2006","unstructured":"Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838\u20131846","journal-title":"Arthritis Rheum"},{"key":"1223_CR73","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00198-008-0653-8","volume":"20","author":"A Cranney","year":"2009","unstructured":"Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, Miller PD, Papapoulos S, Reginster JY, Sambrook PN, Silverman S, Siris E, Adachi JD (2009) Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 20:291\u2013297","journal-title":"Osteoporos Int"},{"key":"1223_CR74","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1185\/030079908X253717","volume":"24","author":"ST Harris","year":"2008","unstructured":"Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 24:237\u2013245","journal-title":"Curr Med Res Opin"},{"key":"1223_CR75","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2008.10.052","volume":"44","author":"AI Sebba","year":"2009","unstructured":"Sebba AI, Emkey RD, Kohles JD, Sambrook PN (2009) Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone 44:423\u2013427","journal-title":"Bone"},{"key":"1223_CR76","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bone.2009.01.002","volume":"44","author":"ST Harris","year":"2009","unstructured":"Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL (2009) Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 44:758\u2013765","journal-title":"Bone"},{"key":"1223_CR77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.0954-6820.2003.01258.x","volume":"255","author":"S Boonen","year":"2004","unstructured":"Boonen S, Haentjens P, Vandenput L, Vanderschueren D (2004) Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes. J Intern Med 255:1\u201312","journal-title":"J Intern Med"},{"key":"1223_CR78","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1185\/030079908X253889","volume":"24","author":"PD Miller","year":"2008","unstructured":"Miller PD, Epstein S, Sedarati F, Reginster JY (2008) Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 24:207\u2013213","journal-title":"Curr Med Res Opin"},{"key":"1223_CR79","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdn038","volume":"19","author":"R Moos von","year":"2008","unstructured":"von Moos R, Caspar CB, Thurlimann B, Angst R, Inauen R, Greil R, Bergstrom B, Schmieding K, Pecherstorfer M (2008) Renal safety profiles of ibandronate 6\u00a0mg infused over 15 and 60\u00a0min: a randomized, open-label study. Ann Oncol 19:1266\u20131270","journal-title":"Ann Oncol"},{"key":"1223_CR80","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","volume":"14","author":"JJ Body","year":"2003","unstructured":"Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstr\u00f6m B (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399\u20131405","journal-title":"Ann Oncol"},{"key":"1223_CR81","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JCD:7:3:255","volume":"7","author":"NB Watts","year":"2004","unstructured":"Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD (2004) Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255\u2013261","journal-title":"J Clin Densitom"},{"key":"1223_CR82","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2796.2008.02010.x","volume":"264","author":"S Boonen","year":"2008","unstructured":"Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, Haentjens P (2008) Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med 264:315\u2013332","journal-title":"J Intern Med"},{"key":"1223_CR83","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1359\/jbmr.071207","volume":"23","author":"JA Gasser","year":"2008","unstructured":"Gasser JA, Ingold P, Venturiere A, Shen V, Green JR (2008) Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 23:544\u2013551","journal-title":"J Bone Miner Res"},{"key":"1223_CR84","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653\u2013661","journal-title":"N Engl J Med"},{"key":"1223_CR85","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1359\/jbmr.080312","volume":"23","author":"MJ Bolland","year":"2008","unstructured":"Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Callon KE, Gamble GD, Reid IR (2008) Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24\u00a0months. J Bone Miner Res 23:1304\u20131308","journal-title":"J Bone Miner Res"},{"key":"1223_CR86","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"1223_CR87","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.070906","volume":"23","author":"RR Recker","year":"2008","unstructured":"Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6\u201316","journal-title":"J Bone Miner Res"},{"key":"1223_CR88","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809","journal-title":"N Engl J Med"},{"key":"1223_CR89","doi-asserted-by":"crossref","unstructured":"Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen E, Magaziner J (2009) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res. doi: 10.1359\/jbmr.090704","DOI":"10.1359\/jbmr.090704"},{"key":"1223_CR90","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2008.12.004","volume":"122","author":"RR Recker","year":"2009","unstructured":"Recker RR, Lewiecki EM, Miller PD, Reiffel J (2009) Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 122:S22\u2013S32","journal-title":"Am J Med"},{"key":"1223_CR91","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00002018-200932030-00004","volume":"32","author":"YK Loke","year":"2009","unstructured":"Loke YK, Jeevanantham V, Singh S (2009) Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 32:219\u2013228","journal-title":"Drug Saf"},{"key":"1223_CR92","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ki.2008.193","volume":"74","author":"S Boonen","year":"2008","unstructured":"Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, Eriksen EF, Miller PD (2008) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 74:641\u2013648","journal-title":"Kidney Int"},{"key":"1223_CR93","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","volume":"17","author":"D Weycker","year":"2006","unstructured":"Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645\u20131652","journal-title":"Osteoporos Int"},{"key":"1223_CR94","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.2106\/JBJS.G.00864","volume":"90","author":"V Rabenda","year":"2008","unstructured":"Rabenda V, Vanoverloop J, Fabri V, Mertens R, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am 90:2142\u20132148","journal-title":"J Bone Joint Surg Am"},{"key":"1223_CR95","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4158\/EP.12.5.522","volume":"12","author":"MP Ettinger","year":"2006","unstructured":"Ettinger MP, Gallagher R, MacCosbe PE (2006) Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 12:522\u2013528","journal-title":"Endocr Pract"},{"key":"1223_CR96","doi-asserted-by":"crossref","unstructured":"Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145\u201355","DOI":"10.1007\/s00198-009-0930-1"},{"key":"1223_CR97","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3899\/jrheum.080759","volume":"36","author":"AA Khan","year":"2009","unstructured":"Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Lentle B, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Mardini MA, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, Ste-Marie LG, Brown J, Evans AW, Rios L, Compston JE (2009) Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 36:478\u2013490","journal-title":"J Rheumatol"},{"key":"1223_CR98","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","volume":"67","author":"MR Allen","year":"2009","unstructured":"Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67:61\u201370","journal-title":"J Oral Maxillofac Surg"},{"key":"1223_CR99","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","volume":"358","author":"BA Lenart","year":"2008","unstructured":"Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. New Engl J Med 358:1304\u20131306","journal-title":"New Engl J Med"},{"key":"1223_CR100","first-page":"18","volume":"64","author":"JP Schneider","year":"2009","unstructured":"Schneider JP (2009) Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 64:18\u201323","journal-title":"Geriatrics"},{"key":"1223_CR101","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","volume":"22","author":"AS Neviaser","year":"2008","unstructured":"Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346\u2013350","journal-title":"J Orthop Trauma"},{"key":"1223_CR102","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.injury.2007.08.036","volume":"39","author":"EB Kwek","year":"2008","unstructured":"Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224\u2013231","journal-title":"Injury"},{"key":"1223_CR103","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1359\/jbmr.070609","volume":"22","author":"RD Chapurlat","year":"2007","unstructured":"Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, Delmas P (2007) Microcrack frequency and bone turnover in osteoporotic women on long term bisphosphonates: a bone biopsy study. J Bone Miner Res 22:1502\u20131509","journal-title":"J Bone Miner Res"},{"key":"1223_CR104","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bone.2007.04.198","volume":"41","author":"JJ Stepan","year":"2007","unstructured":"Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, Fahrleitner-Pammer A, Petto H, Westmore M, Michalsky D, Sato M, Dobnig H (2007) Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41:378\u2013385","journal-title":"Bone"},{"key":"1223_CR105","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1359\/jbmr.081247","volume":"24","author":"B Abrahamsen","year":"2009","unstructured":"Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095\u20131102","journal-title":"J Bone Miner Res"},{"key":"1223_CR106","first-page":"690","volume":"14","author":"DW Dempster","year":"1993","unstructured":"Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R (1993) Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690\u2013709","journal-title":"Endocr Rev"},{"key":"1223_CR107","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","volume":"357","author":"E Canalis","year":"2007","unstructured":"Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905\u2013916","journal-title":"N Engl J Med"},{"key":"1223_CR108","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"1223_CR109","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1210\/jc.2006-2439","volume":"92","author":"PD Miller","year":"2007","unstructured":"Miller PD, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R (2007) Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab 92:3535\u20133541","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR110","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","volume":"165","author":"MR McClung","year":"2005","unstructured":"McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762\u20131768","journal-title":"Arch Intern Med"},{"key":"1223_CR111","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","volume":"20","author":"P Chen","year":"2005","unstructured":"Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962\u2013970","journal-title":"J Bone Miner Res"},{"key":"1223_CR112","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1210\/jc.2003-1703","volume":"90","author":"H Dobnig","year":"2005","unstructured":"Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, Pavo I, Wang J, Eriksen EF (2005) Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970\u20133977","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR113","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","volume":"18","author":"R Marcus","year":"2003","unstructured":"Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18\u201323","journal-title":"J Bone Miner Res"},{"key":"1223_CR114","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1210\/jc.2007-0239","volume":"92","author":"B Dawson-Hughes","year":"2007","unstructured":"Dawson-Hughes B, Chen P, Krege JH (2007) Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. J Clin Endocrinol Metab 92:4630\u20134636","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR115","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","volume":"164","author":"R Lindsay","year":"2004","unstructured":"Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164:2024\u20132030","journal-title":"Arch Intern Med"},{"key":"1223_CR116","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207\u20131215","journal-title":"N Engl J Med"},{"key":"1223_CR117","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/JBMR.050714","volume":"20","author":"C Deal","year":"2005","unstructured":"Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH (2005) Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20:1905\u20131911","journal-title":"J Bone Miner Res"},{"key":"1223_CR118","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745\u2013751","journal-title":"J Bone Miner Res"},{"key":"1223_CR119","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1210\/jc.2003-030768","volume":"88","author":"AB Hodsman","year":"2003","unstructured":"Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R (2003) Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212\u20135220","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR120","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326\u2013339","journal-title":"Ann Intern Med"},{"key":"1223_CR121","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1742-1241.2006.01249.x","volume":"61","author":"JY Reginster","year":"2007","unstructured":"Reginster JY, Malaise O, Neuprez A, Bruyere O (2007) Strontium ranelate in the prevention of osteoporotic fractures. Int J Clin Pract 61:324\u2013328","journal-title":"Int J Clin Pract"},{"key":"1223_CR122","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459\u2013468","journal-title":"N Engl J Med"},{"key":"1223_CR123","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/8756-3282(96)00080-4","volume":"18","author":"E Canalis","year":"1996","unstructured":"Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ (1996) The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18:517\u2013523","journal-title":"Bone"},{"key":"1223_CR124","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0014-2999(02)02040-X","volume":"450","author":"R Baron","year":"2002","unstructured":"Baron R, Tsouderos Y (2002) In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Euro J Pharmacol 450:11\u201317","journal-title":"Euro J Pharmacol"},{"key":"1223_CR125","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1359\/jbmr.2003.18.6.1082","volume":"18","author":"N Takahashi","year":"2003","unstructured":"Takahashi N, Sasaki T, Tsouderos Y, Suda T (2003) S 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 18:1082\u20131087","journal-title":"J Bone Miner Res"},{"key":"1223_CR126","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1074\/jbc.M801668200","volume":"284","author":"AS Hurtel-Lemaire","year":"2009","unstructured":"Hurtel-Lemaire AS, Mentaverri R, Caudrillier A, Cournarie F, Wattel A, Kamel S, Terwilliger EF, Brown EM, Brazier M (2009) The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways. J Biol Chem 284:575\u2013584","journal-title":"J Biol Chem"},{"key":"1223_CR127","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bone.2007.08.043","volume":"42","author":"E Bonne lye","year":"2008","unstructured":"Bonne lye E, Chabadel A, Saltel F, Jurdic P (2008) Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42:129\u2013138","journal-title":"Bone"},{"key":"1223_CR128","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00198-008-0815-8","volume":"20","author":"SD Bain","year":"2009","unstructured":"Bain SD, Jerome C, Shen V, Dupin-Roger I, Ammann P (2009) Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 20:1417\u20131428","journal-title":"Osteoporos Int"},{"key":"1223_CR129","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","volume":"90","author":"JY Reginster","year":"2005","unstructured":"Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816\u20132822","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR130","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/s001980200129","volume":"13","author":"JY Reginster","year":"2002","unstructured":"Reginster JY, Spector T, Badurski J (2002) A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The strontium ranelate phase III program. Osteoporos Int 13:S30","journal-title":"Osteoporos Int"},{"key":"1223_CR131","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.23461","volume":"58","author":"JY Reginster","year":"2008","unstructured":"Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ (2008) Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 58:1687\u20131695","journal-title":"Arthritis Rheum"},{"key":"1223_CR132","first-page":"S131","volume":"19","author":"JY Reginster","year":"2008","unstructured":"Reginster JY, Sawicki A, Roces-Varela (2008) Strontium ranelate: 8\u00a0years efficacy on vertebral and nonvertebral fractures in post menopausal osteoporotic women. Osteoporos Int 19:S131\u2013S132","journal-title":"Osteoporos Int"},{"key":"1223_CR133","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1359\/jbmr.060101","volume":"21","author":"C Roux","year":"2006","unstructured":"Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawicki A, Tulassay Z, Luisetto G, Padrino JM, Doyle D, Prince R, Fardellone P, Sorensen OH, Meunier PJ (2006) Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21:536\u2013542","journal-title":"J Bone Miner Res"},{"key":"1223_CR134","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1359\/jbmr.060404","volume":"21","author":"E Seeman","year":"2006","unstructured":"Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J, Kaufman JM, Hoszowski K, Varela AR, Fiore C, Brixen K, Reginster JY, Boonen S (2006) Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 21:1113\u20131120","journal-title":"J Bone Miner Res"},{"key":"1223_CR135","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1359\/jbmr.071105","volume":"23","author":"E Seeman","year":"2008","unstructured":"Seeman E, Devogelaer JP, Lorenc R, Spector T, Brixen K, Balogh A, Stucki G, Reginster JY (2008) Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 23:433\u2013438","journal-title":"J Bone Miner Res"},{"key":"1223_CR136","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1210\/jc.2006-2758","volume":"92","author":"O Bruyere","year":"2007","unstructured":"Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, Brixen K, Devogelaer JP, Diaz-Curiel M, Albanese C, Kaufman JM, Pors-Nielsen S, Reginster JY (2007) Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 92:3076\u20133081","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR137","doi-asserted-by":"crossref","unstructured":"Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, Hamel C, Ortiz Z, Peterson J, Adachi J, Tugwell P, Guyatt G; Osteoporosis Methodology Group; Osteoporosis Research Advisory Group (2004) Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev CD004526","DOI":"10.1002\/14651858.CD004526.pub2"},{"key":"1223_CR138","unstructured":"European Medicines Agency (EMEA) (2007) Question and answers on the safety of Protelos\/Osseor (strontium ranelate) Ref. EMEA\/534613\/2007. Available via http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/protelos\/Protelos_Q&A_53461307en.pdf . Accessed 1 Oct 2008"},{"key":"1223_CR139","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2125.2008.03273.x","volume":"66","author":"A Grosso","year":"2008","unstructured":"Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L (2008) Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 66:689\u2013694","journal-title":"Br J Clin Pharmacol"},{"key":"1223_CR140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000069956","volume":"206","author":"S Tas","year":"2003","unstructured":"Tas S, Simonart T (2003) Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology 206:353\u2013356","journal-title":"Dermatology"},{"key":"1223_CR141","doi-asserted-by":"crossref","first-page":"b1494","DOI":"10.1136\/bmj.b1494","volume":"338","author":"M Sainz","year":"2009","unstructured":"Sainz M, del Pozo JG, Arias LH, Carvajal A (2009) Strontium ranelate may cause alopecia. BMJ 338:b1494","journal-title":"BMJ"},{"key":"1223_CR142","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","volume":"20","author":"T Suda","year":"1999","unstructured":"Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345\u2013357","journal-title":"Endocr Rev"},{"key":"1223_CR143","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","volume":"97","author":"J Li","year":"2000","unstructured":"Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 97:1566\u20131571","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1223_CR144","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309\u2013319","journal-title":"Cell"},{"key":"1223_CR145","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","volume":"97","author":"JJ Body","year":"2003","unstructured":"Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Marriette X, Williams CD, Nakanishi A, Holloway D, Dunstan CR, Bekker PJ (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97:887\u2013892","journal-title":"Cancer"},{"key":"1223_CR146","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059\u20131066","journal-title":"J Bone Miner Res"},{"key":"1223_CR147","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1210\/endo.140.9.7131","volume":"140","author":"LC Hofbauer","year":"1999","unstructured":"Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL (1999) Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140:4367\u20134370","journal-title":"Endocrinology"},{"key":"1223_CR148","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","volume":"111","author":"G Eghbali-Fatourechi","year":"2003","unstructured":"Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221\u20131230","journal-title":"J Clin Invest"},{"key":"1223_CR149","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821\u2013831","journal-title":"N Engl J Med"},{"key":"1223_CR150","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","volume":"22","author":"EM Lewiecki","year":"2007","unstructured":"Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22:1832\u20131841","journal-title":"J Bone Miner Res"},{"key":"1223_CR151","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New Engl J Med 361:756\u2013765","journal-title":"New Engl J Med"},{"key":"1223_CR152","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161","journal-title":"J Bone Miner Res"},{"key":"1223_CR153","first-page":"S81","volume":"23","author":"S Cummings","year":"2008","unstructured":"Cummings S, Eastell R, Ensrud KE, Reid DM, Vukicevic S, La Croix A et al (2008) The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial. J Bone Miner Res 23:S81, Abstr. 1288","journal-title":"J Bone Miner Res"},{"key":"1223_CR154","first-page":"S470","volume":"23","author":"R Downs","year":"2008","unstructured":"Downs R, Moffett AH, Ghosh A, Cox DA, Harper K (2008) Effects of arzoxifene on bone turnover and safety in postmenopausal women with low bone mass: results from a 6-month phase 2 study. J Bone Miner Res 23:S470\u2013S471","journal-title":"J Bone Miner Res"},{"key":"1223_CR155","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","volume":"23","author":"SL Silverman","year":"2008","unstructured":"Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantiene GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923\u20131934","journal-title":"J Bone Miner Res"},{"key":"1223_CR156","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1359\/jbmr.2001.16.10.1739","volume":"16","author":"GB Stroup","year":"2001","unstructured":"Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW, Ru Y, Vasko-Moser JA, Smith BR, Tomaszek T, Gowen M (2001) Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 16:1739\u20131746","journal-title":"J Bone Miner Res"},{"key":"1223_CR157","first-page":"S82","volume":"23","author":"MR McClung","year":"2008","unstructured":"McClung MR, Bone H, Cosman E, Roux C, Verbruggen N, Hustad C, DaSilva C, Santora A, Ince A (2008) A randomized, double-blind, placebo-controlled study of odanacatib (MK-822) in the treatment of postmenopausal women with low bone mineral density: 24-month results. J Bone Miner Res 23:S82","journal-title":"J Bone Miner Res"},{"key":"1223_CR158","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","volume":"24","author":"X Li","year":"2009","unstructured":"Li X, Ominski MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C (2009) Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578\u2013588","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00198-010-1223-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T20:36:17Z","timestamp":1711485377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-010-1223-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,18]]},"references-count":158,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["1223"],"URL":"https:\/\/doi.org\/10.1007\/s00198-010-1223-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,18]]}}}